Therapeutic Response

Wild type KRAS and Wild type NRAS status confers therapeutic sensitivity to Panitumumab in patients with Colorectal Adenocarcinoma.

Statements

Source and description
Vectibix (panitumumab) [product monograph]. HC. Health Canada approved panitumumab as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.